Site Overlay


Por medio del Acuerdo de , la Comisión de Regulación en Salud – CRES-, introdujo ajustes al Acuerdo , por medio del cual se. acuerdo de cres pdf. Quote. Postby Just» Tue Aug 28, am. Looking for acuerdo de cres pdf. Will be grateful for any help! Top. P P 11 1 P(|racu|ra |loslalo) 15 rd de oase lao|ela o cápsu|a. P Z0 1 0u|r|ra d|c|o(r|d(alo rd/2 rL so|uc|ór |rveclao|e. P 10 1 0u|r|ra.

Author: Gardalrajas Vucage
Country: Botswana
Language: English (Spanish)
Genre: Marketing
Published (Last): 10 November 2008
Pages: 437
PDF File Size: 13.28 Mb
ePub File Size: 10.92 Mb
ISBN: 544-4-59163-670-5
Downloads: 84811
Price: Free* [*Free Regsitration Required]
Uploader: Shaktilmaran

Any incomplete record was replaced by the complete record of another randomized patient from the same city and of the same sex and age group. Mean differences were determined by a nonparametric test i. A statistically significant association was found between the rate of dyslipidemia control and the following variables: Given that multiple studies have documented that hypercholesterolemia increases the risk of developing CVD, its control has become a goal of physicians 1. Information on sociodemographic and anthropometric characteristics, risk factors, and pharmacological and laboratory variables were obtained from medical records.

There was a problem providing the content you requested

Issues and evidence for the management of dyslipidaemia in primary care. Data collection The quality of the patient records was reviewed by two physicians.

A difference was found between the initial and final LDL-C levels despite the statistically-significant reduction percentages, which are lower than those reported for lovastatin by other studies 4. It has been shown that quality-of-care improvement programs for acuedo with metabolic disorders can achieve great changes and reduce complications through effective therapy According to the results of the present study, the prevalent characteristics of patients in the high cardiovascular risk group with uncontrolled dyslipidemia are two or more of following variables: Therapy adherence was determined by the degree to which the patient complied with the recommendations recorded by the doctor in the medical record.


Additionally, differences between the initial mean: The effectiveness of lipid-lowering therapies was established based on the following groups, defined according to the ATP III goal set and whether it was achieved or not: There is also evidence that earlier interventions produce more cost-effective results Prescription patterns for antilipidemic drugs in a group of Colombian patients. Arterioscler Thromb Vasc Biol.

In the patients comprising risk acuedro 1, The use of lipid-lowering drugs was examined, and the number of patients receiving monotherapy was as follows: Also of note is that the entire sample of patients received generic drugs. Eur J Gen Pract. In Colombia, the mortality rate due to cardiovascular disease CVD ranks first among women, and second among men.

Resultado de busqueda | Consultorsalud

On average, there was a 4. Pan American Health Organization. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: Low-density lipoprotein cholesterol LDL-C levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.

Subjects were predominantly female It has even been suggested that a suboptimal statin treatment may increase the risk of coronary events Among those at moderate risk, Additionally, the presence of comorbidities, such as diabetes mellitus, which contribute to cardiovascular risk, should be evaluated for treatment with the drug of choice and at the appropriate dose Colombia has adopted an essential acurdo list into the Plan Obligatorio de Salud Mandatory Health Plan, POS ; initially it included three generic agents for dyslipidemia management: Statistical software was used to select subjects in a stratified random sampling, by city, from among the 8 patients receiving lipid-lowering cre out of a total of 3.

Controlled versus acuerrdo dyslipidemic patients For risk group 1, the average dose of lovastatin was higher in the controlled patients than in the uncontrolled 74 vs. The present study evaluated the effectiveness of lipid-lowering therapies in dislipidemic patients affiliated with the SGSSS.


The reasons for this discrepancy may include using a lower dose than recommended, problems with treatment adherence, and a lack of medical management goals 19, 24, Of the 25 patients in risk group 3, Distribution and correlates of lipids and lipoproteins in elderly Japanese-American men. This research was funded by Audifarma Ackerdo.

acuerdo 029 de 2011 cres pdf

Furthermore, the importance of the starting dose to the overall effectiveness of the therapy has been underscored by a study showing that the percentage reduction in LDL-C levels achieved with the initial dose of statins was strongly correlated with the proportion of patients who maintained their goals at 54 weeks; therefore, it is recommended that therapy start at a dose that should achieve the goal, and if insufficient, be increased significantly to achieve it Eur J Cardiovasc Prev Rehabil.

None of the other three groups showed statistically-significant differences between doses of lovastatin. Controlled versus uncontrolled dyslipidemic patients. Am J Cardiovasc Drugs. Determinar la eficacia del tratamiento hipolipemiante en una muestra de pacientes afiliados al Sistema General de Seguridad Social en Salud de Colombia.

However, with high doses of this drug, the values are quite close to the results of one study 6. LDL-C measurements taken in the 6 months prior to the study were available for cases Several associated factors were also examined: Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The patients were being treated with lovastatin Table 2 shows the results of the bivariate analysis that compared the subgroup of patients whose total-C was controlled versus the uncontrolled subgroup.